FDA Approves Utebzi as First Oral Carbapenem Antibiotic for Complicated UTIs
On June 17, 2026, the U.S. Food and Drug Administration (FDA) approved Utebzi (tebipenem pivoxil) tablets, developed by Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults who have limited or no alternative oral treatment options.
This landmark approval represents a significant public health milestone, as Utebzi is the first-ever oral carbapenem antibiotic approved in the United States.
Clinical and Practical Significance
Carbapenems are broad-spectrum, highly effective beta-lactam antibiotics that are typically reserved as a "last line of defense" for severe or multi-drug resistant (MDR) bacterial infections. Historically, however, carbapenems have only been available as intravenous (IV) formulations, requiring patients to be hospitalized or to have central venous access lines placed for outpatient parenteral antimicrobial therapy (OPAT).
The approval of Utebzi provides a critical IV-to-oral step-down option. Hospitalized patients recovering from severe, drug-resistant urinary infections can now be transitioned to oral tablets to complete their treatment course at home. This shift is expected to significantly:
- Reduce hospital lengths of stay
- Lower overall healthcare costs
- Minimize the risk of hospital-acquired infections (nosocomial infections)
- Improve patient quality of life and convenience
Phase 3 Trial Supporting Approval
The FDA's approval of Utebzi was based on robust data from a global, randomized, double-blind, double-dummy, noninferiority Phase 3 clinical trial (NCT06059846). The trial randomized 1,690 hospitalized adult patients with cUTIs or pyelonephritis to receive either:
- Utebzi: 600 mg administered orally every 6 hours
- Imipenem-Cilastatin: 500 mg administered intravenously every 6 hours
The treatment duration was 7 to 10 days. The primary efficacy endpoint was a composite of clinical cure (complete resolution of infection signs and symptoms) and microbiological response (reduction of baseline pathogens to <10^3 CFU/mL) at a follow-up visit. The study demonstrated that Utebzi achieved composite response rates that were statistically comparable (noninferior) to the intravenous imipenem-cilastatin standard of care.
Safety, Warnings, and Designations
Utebzi’s safety profile was found to be comparable to other beta-lactam antibiotics. The most common adverse events reported include diarrhea, headache, nausea, abdominal pain, increased liver transaminases, and Clostridioides difficile infection.
Utebzi is contraindicated in patients with:
- A history of severe hypersensitivity or allergic reactions to tebipenem pivoxil, other carbapenems, or beta-lactam antibacterials.
- Primary or secondary carnitine deficiency, or inborn errors of metabolism that could cause a clinically significant carnitine deficiency (since tebipenem pivoxil metabolism can lead to carnitine depletion).
The FDA reviewed and approved Utebzi under Priority Review and Fast Track designations, and it was granted Qualified Infectious Disease Product (QIDP) designation under the GAIN Act to incentivize the development of novel antibacterial therapies.